Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
2016 updated EULAR evidence-based recommendations for the management of gout
Background New drugs and new evidence concerning the use of established treatments
have become available since the publication of the first European League Against …
have become available since the publication of the first European League Against …
[HTML][HTML] Gout: An old disease in new perspective–A review
Gout is a picturesque presentation of uric acid disturbance. It is the most well understood
and described type of arthritis. Its epidemiology is studied. New insights into the …
and described type of arthritis. Its epidemiology is studied. New insights into the …
[HTML][HTML] The British Society for Rheumatology guideline for the management of gout
M Hui, A Carr, S Cameron, G Davenport… - …, 2017 - academic.oup.com
Gout is the most common cause of inflammatory arthritis worldwide. In UK general practice,
the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the …
the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the …
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
MA Becker, HR Schumacher, LR Espinoza… - Arthritis research & …, 2010 - Springer
Introduction The purpose of this study was to compare urate-lowering (UL) efficacy and
safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA)≥ 8.0 …
safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA)≥ 8.0 …
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind …
HR Schumacher Jr, MA Becker… - Arthritis Care & …, 2008 - Wiley Online Library
Objective To compare the urate‐lowering efficacy and safety of febuxostat, allopurinol, and
placebo in a large group of subjects with hyperuricemia and gout, including persons with …
placebo in a large group of subjects with hyperuricemia and gout, including persons with …
Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes
Importance Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-
glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of …
glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of …
Management of gout and hyperuricemia in CKD
Hyperuricemia and gout, the clinical manifestation of monosodium urate crystal deposition,
are common in patients with chronic kidney disease (CKD). Although the presence of CKD …
are common in patients with chronic kidney disease (CKD). Although the presence of CKD …
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol
Objective Allopurinol is the most commonly used urate‐lowering therapy in gout. Allopurinol
hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event. Dosing …
hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event. Dosing …
Comparative effectiveness of allopurinol and febuxostat in gout management
Background The relative efficacy and safety of allopurinol and febuxostat when used
according to current guidelines for the treatment of hyperuricemia are unknown. This double …
according to current guidelines for the treatment of hyperuricemia are unknown. This double …
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout
Kelsey M. Jordan, J. Stewart Cameron1, Michael Snaith2, Weiya Zhang3, Michael Doherty3,
Jonathan Seckl4, Aroon Hingorani5, Richard Jaques6, George Nuki7 on behalf of the British …
Jonathan Seckl4, Aroon Hingorani5, Richard Jaques6, George Nuki7 on behalf of the British …